©The Author(s) 2025.
World J Exp Med. Dec 20, 2025; 15(4): 110482
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.110482
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.110482
Table 3 Comparative summary of nanocarrier-based pinocembrin formulations
| Formulation type | Particle size (nm) | Entrapment efficiency (%) | Fold bioavailability increase | Half-life (t1/2) extension | Ref. |
| MPEG-PDLLA micelles (PCB-M) | 27.6 ± 0.17 | 90.5 | 5.3-fold | 1.2 hours increased to 2.6 hours | Cao et al[36], 2022 |
| TPGS micelles | Approximately 50 | Approximately 85 | 4.8-fold | Not reported | Sun et al[84], 2016 |
| TPGS liposomes | Approximately 120 | > 85 | 1.96-fold | 1.2 hours increased to 14.2 hours | Tan et al[85], 2013 |
- Citation: Singla N, Mittal P, Babu MA, V Menon S, Ray S, Ali H, Purohit M, Goyal K, Mishra R, Hussain MS, Rekha A, Gupta G. Pinocembrin as a novel anti-cancer agent: Exploring preclinical evidence along with therapeutic potential. World J Exp Med 2025; 15(4): 110482
- URL: https://www.wjgnet.com/2220-315x/full/v15/i4/110482.htm
- DOI: https://dx.doi.org/10.5493/wjem.v15.i4.110482